心脏代谢共病对欧洲银屑病关节炎患者首次b/tsDMARD治疗的影响
基于欧洲8个风湿病注册库中5299例2015年后起始首次b/tsDMARD的银屑病关节炎患者,36%至少有一种心脏代谢共病。共病患者年龄更大、疾病活动度更高、残疾更重;TNF抑制剂处方占76%,IL-17抑制剂使用随共病负担增加而上升,JAK抑制剂下降。
要点
- 36%的银屑病关节炎患者至少有一种心脏代谢共病,共病患者基线疾病活动度更高。
- TNF抑制剂仍是最常用一线b/tsDMARD(76%),IL-17抑制剂使用随共病负担增加。
核心结论
- 心脏代谢共病患者起始首次b/tsDMARD时疾病活动度更高,共病负担影响处方模式,并与治疗保留率轻度降低相关。
研究设计与样本
- 基于欧洲8个风湿病注册库的回顾性队列研究,纳入5299例2015年或之后起始首次b/tsDMARD且基线有五种心脏代谢共病信息的银屑病关节炎患者。
主要发现
- 36%的患者至少有一种心脏代谢共病,共病患者年龄更大、疾病活动度更高、残疾更重。
- 无论共病状态,76%的患者处方TNF抑制剂;IL-17抑制剂使用率随共病负担(0/1/≥2)分别为13%/18%/19%,JAK抑制剂分别为2.3%/1.6%/0.8%。
- 治疗撤药风险在共病负担较高者仅轻度升高(一种共病:HR 1.19,95%CI 1.02至1.40;≥2种共病:HR 1.18,95%CI 0.98至1.42)。
临床怎么用
- 对合并心脏代谢共病的银屑病关节炎患者,起始b/tsDMARD时应关注更高的疾病活动度并个体化选择药物。
- 肥胖可能与治疗保留率轻度降低相关,临床可加强体重管理和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate associations between cardiometabolic comorbidities and clinical characteristics, prescription patterns and retention of first biologic/targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) in patients with psoriatic arthritis (PsA). METHODS: Patients with PsA initiating a first b/tsDMARD treatment in 2015 or later were identified in eight European rheumatology registries. Patients with information on five cardiometabolic comorbidities (obesity, dyslipidaemia, diabetes, hypertension, ischaemic heart disease) at treatment start (baseline) were included. All analyses were conducted according to patients' comorbidity burden (count: 0/1/≥2) and status (presence/absence of each comorbidity). Patient characteristics and prescription patterns were described. Twelve-month treatment retention rates were estimated and compared using Kaplan-Meier plots, log-rank tests and multivariable Cox regression analyses. RESULTS: Among 5299 patients, 36% had at least one cardiometabolic comorbidity. Patients with comorbidity were older, had higher disease activity and more disability. Regardless of comorbidity, most patients were prescribed a tumour necrosis factor inhibitor (76%). The use of interleukin-17 inhibitors increased with comorbidity burden (0/1/≥2 comorbidities: 13%/18%/19%), whereas Janus kinase inhibitor use declined (2.3%/1.6%/0.8%). Retention rates were marginally lower with higher comorbidity burden (80%/76%/78%) (log-rank, p=0.036) and obesity (absent 79% vs present 77%) (log-rank, p=0.04). The risk of treatment withdrawal was only marginally higher in patients with higher comorbidity burden (one comorbidity: HR 1.19; 95% CI 1.02 to 1.40; ≥2 comorbidities: HR 1.18; 0.98 to 1.42). CONCLUSION: Patients with cardiometabolic comorbidities had higher disease activity at treatment initiation of the first b/tsDMARD. Prescription patterns varied with comorbidity burden. Cardiometabolic comorbidity burden, especially obesity, was associated with marginally lower treatment retention.
引用
- Ahmadzay ZF, Ørnbjerg LM, Østergaard M, et al. Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis. RMD Open. 2026. PMID: 42097690. doi:10.1136/rmdopen-2025-006477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。